Sign in
Enrolling by invitationPhase 2

An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis

Key facts

Who runs it
Oruka Therapeutics, Inc.
Where
Fountain Valley, Milford, New Brighton, Warrenton, and Wilmington, United StatesSee the 5 sitesAlso in 1 other country, 3 sites
Trial code
Status
Enrolling by invitation
Phase
Phase 2
People taking part
160 people, planned
Started
26 Oct 2026
Expected to end
1 Sept 2029
Type of study
Interventional, 3 groups
Treatments tested
  • ORKA-002
Record updated
12 November 2026

Who can take part

Age
18 years to 79 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Signed informed consent by participants from previous trial choosing to transition into the Open-label study
  • Participants who have successfully completed the preceding trial
  • For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit
  • For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception

Who cannot take part

  • Participants who experienced any adverse events with ORKA-002 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-002
  • Participants whom the Investigator feels would not benefit from treatment with open-label ORKA-002
  • Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial
  • Participants who, while in ORKA-002-212, developed a new intercurrent illness or diagnosis/suspected diagnosis which, in the opinion of the Investigator, indicates that continued treatment and/or participation in the study is not in the participant's best interest
  • Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001
  • Participant is pregnant or breastfeeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 79 years old?

Where in United States

Also in 1 other country, 3 sites

  • Fountain Valley, CaliforniaHospital not named in the registryEnrolling by invitation
  • Milford, MassachusettsHospital not named in the registryEnrolling by invitation
  • New Brighton, MinnesotaHospital not named in the registryEnrolling by invitation
  • Warrenton, OregonHospital not named in the registryEnrolling by invitation
  • Wilmington, North CarolinaHospital not named in the registryEnrolling by invitation

About the trial

What the trial wants to find out

An open-label study with maintenance dosing to evaluate the long-term safety and efficacy of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

The 3 groups in the trial

  • ORKA-002 (High Dose)Treatment being tested

    Participants will receive ORKA-002 every 6 moinths per protocol.

    Treatment: ORKA-002

  • ORKA-002 (Low Dose)Treatment being tested

    Participants will receive ORKA-002 every 6 months per the protocol.

    Treatment: ORKA-002

  • ORKA-002 (Mid-Dose)Treatment being tested

    Participants will receive ORKA-002 every 6 moinths per the protocol

    Treatment: ORKA-002

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-label Study With Maintenance Dosing to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis
Fit questions
Built from NCT07933783, who can take part
Record updated
12 November 2026